Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2020

Open Access 01-12-2020 | Colorectal Cancer | Original research

Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model

Authors: Siao-Syun Guan, Cheng-Tien Wu, Tse-Zung Liao, Tsai-Yueh Luo, Kun-Liang Lin, Shing-Hwa Liu

Published in: EJNMMI Research | Issue 1/2020

Login to get access

Abstract

Background

Cancer stem cells (CSCs) are involved in drug resistance, metastasis, and relapse of cancers, which can significantly affect tumor therapy. Hence, to develop specifically therapeutic target probe at CSCs for improvement of survival and quality of life of cancer patients is urgently needed. The CD166 protein has been suggested to be involved in colorectal cancer (CRC) tumorigenesis and to be considered a marker for colorectal CSCs (CRCSCs) detection. In this study, therefore, we attend to apply a nuclear imaging agent probe, Glycine18-Cystine-linked CD166-targeted peptides (CD166tp-G18C), to detect the changes of CD166 level in a CRC xenograft mouse model.

Results

We isolated the CD166-positive cells from the HCT15 CRC cell line (CD166+HCT15) and evaluated their morphology and ability of clone formation, migration, protein expression, and drug resistance. The CD166-positive HCT15 cells display the CSCs characteristics. We discovered and designed a CD166-targeted peptide (CD166tp-G18C) as a targeted probe of CRC stem-like cell for cell binding assay. The CD166tp-G18C confirmed the CD166 protein targeting ability in CD166+HCT15 cells. The diethylenetriaminopentaacetic acid (DTPA)-conjugated CD166tp-G18C further was labeled with indium-111 (111In-DTPA-CD166tp-G18C) as nuclear imaging agent for imaging and bio-distribution analysis in vivo. Finally, we observed that the 111In-DTPA-CD166tp-G18C was significantly enhanced in tumor tissues of CD166+HCT15 xenograft mice as compared to the non-CD166tp-G18C control.

Conclusions

Our results indicated that the indium-111-labeled CD166tp-G18C may be served as a powerful tool for colorectal CSCs nuclear imaging in the CRC patients.
Literature
1.
2.
Fitzmaurice C, Allen C, Barber RM, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2017;3:524–48.PubMedCrossRef
3.
Arnold M, Sierra MS, Laversanne M, et al. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66:683–91.CrossRefPubMed
4.
5.
Agliano A, Calvo A, Box C. The challenge of targeting cancer stem cells to halt metastasis. Semin Cancer Biol. 2017;44:25–42.PubMedCrossRef
6.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445:111–5.PubMedCrossRef
7.
Lu J, Ye X, Fan F, et al. Endothelial cells promote the colorectal cancer stem cell phenotype through a soluble form of Jagged-1. Cancer Cell. 2013;23:171–85.PubMedPubMedCentralCrossRef
8.
9.
Guo M, Dou J. Advances and perspectives of colorectal cancer stem cell vaccine. Biomed Pharmacother. 2015;76:107–20.PubMedCrossRef
10.
Jones MF, Hara T, Francis P, et al. The CDX1-microRNA-215 axis regulates colorectal cancer stem cell differentiation. Proc Natl Acad Sci U S A. 2015;112:E1550–8.PubMedPubMedCentral
11.
Zhai H, Fesler A, Ba Y, Wu S, Ju J. Inhibition of colorectal cancer stem cell survival and invasive potential by hsa-miR-140-5p mediated suppression of Smad2 and autophagy. Oncotarget. 2015;6:19735–46.PubMedPubMedCentralCrossRef
12.
13.
Bowen MA, Patel DD, Li X, et al. Cloning, mapping, and characterization of activated leukocyte-cell adhesion molecule (ALCAM), a CD6 ligand. J Exp Med. 1995;181:2213–20.PubMedCrossRef
14.
Patel DD, Wee SF, Whichard LP, et al. Identification and characterization of a 100-kD ligand for CD6 on human thymic epithelial cells. J Exp Med. 1995;181:1563–8.PubMedCrossRef
15.
Van Kempen LC, Nelissen JM, Degen WG, et al. Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem. 2001;276:25783–90.PubMedCrossRef
16.
Cayrol R, Wosik K, Berard JL, et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat Immunol. 2008;9:137–45.PubMedCrossRef
17.
Ohneda O, Ohneda K, Arai F, et al. ALCAM (CD166): its role in hematopoietic and endothelial development. Blood. 2001;98:2134–42.PubMedCrossRef
18.
Tachezy M, Zander H, Gebauer F, et al. Activated leukocyte cell adhesion molecule (CD166)--its prognostic power for colorectal cancer patients. J Surg Res. 2012;177:e15–20.PubMedCrossRef
19.
Verma A, Shukla NK, Deo SV, Gupta SD, Ralhan R. MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology. 2005;68:462–70.PubMedCrossRef
20.
Klein WM, Wu BP, Zhao S, et al. Increased expression of stem cell markers in malignant melanoma. Mod Pathol. 2007;20:102–7.PubMedCrossRef
21.
Ihnen M, Muller V, Wirtz RM, et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat. 2008;112:419–27.PubMedCrossRef
22.
Mezzanzanica D, Fabbi M, Bagnoli M, et al. Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients. Clin Cancer Res. 2008;14:1726–33.PubMedCrossRef
23.
Minner S, Kraetzig F, Tachezy M, et al. Low activated leukocyte cell adhesion molecule expression is associated with advanced tumor stage and early prostate-specific antigen relapse in prostate cancer. Hum Pathol. 2011;42:1946–52.PubMedCrossRef
24.
25.
Vaiopoulos AG, Kostakis ID, Koutsilieris M, Papavassiliou AG. Colorectal cancer stem cells. Stem Cells. 2012;30:363–71.PubMedCrossRef
26.
Weichert W, Knosel T, Bellach J, Dietel M, Kristiansen G. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol. 2004;57:1160–4.PubMedPubMedCentralCrossRef
27.
Sim SH, Kang MH, Kim YJ, et al. P21 and CD166 as predictive markers of poor response and outcome after fluorouracil-based chemoradiotherapy for the patients with rectal cancer. BMC Cancer. 2014;14:241.PubMedPubMedCentralCrossRef
28.
Beck A, Goetsch L, Dumontet C, Corvaia N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat Rev Drug Discov. 2017;16:315–37.PubMedCrossRef
29.
30.
Hansel TT, Kropshofer H, Singer T, Mitchell JA, George AJ. The safety and side effects of monoclonal antibodies. Nat Rev Drug Discov. 2010;9:325–38.PubMedCrossRef
31.
David A. Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Adv Drug Deliv Rev. 2017;119:120–42.PubMedCrossRef
32.
33.
Wang Q, Li SB, Zhao YY, et al. Identification of a sodium pump Na(+)/K(+) ATPase alpha1-targeted peptide for PET imaging of breast cancer. J Control Release. 2018;281:178–88.PubMedCrossRef
34.
Peng L, Shang W, Guo P, et al. Phage display-derived peptide-based dual-modality imaging probe for bladder cancer diagnosis and resection postinstillation: a preclinical study. Mol Cancer Ther. 2018;17:2100–11.PubMedCrossRef
35.
Di Stefano AB, Iovino F, Lombardo Y, et al. Survivin is regulated by interleukin-4 in colon cancer stem cells. J Cell Physiol. 2010;225:555–61.PubMedCrossRef
36.
Elbadawy M, Usui T, Yamawaki H, Sasaki K. Emerging roles of C-Myc in cancer stem cell-related signaling and resistance to cancer chemotherapy: a potential therapeutic target against colorectal cancer. Int J Mol Sci. 2019;20.
37.
38.
39.
Lingasamy P, Tobi A, Haugas M, et al. Bi-specific tenascin-C and fibronectin targeted peptide for solid tumor delivery. Biomaterials. 2019;219:119373.PubMedCrossRef
40.
41.
Price EW, Orvig C. Matching chelators to radiometals for radiopharmaceuticals. Chem Soc Rev. 2014;43:260–90.PubMedCrossRef
42.
43.
O'brien-Ball C, Biddle A. Reprogramming to developmental plasticity in cancer stem cells. Dev Biol. 2017;430:266–74.PubMedCrossRef
44.
Qureshi-Baig K, Ullmann P, Haan S, Letellier E. Tumor-initiating cells: a criTICal review of isolation approaches and new challenges in targeting strategies. Mol Cancer. 2017;16:40.PubMedPubMedCentralCrossRef
45.
Tirino V, Desiderio V, Paino F, et al. Cancer stem cells in solid tumors: an overview and new approaches for their isolation and characterization. FASEB J. 2013;27:13–24.PubMedCrossRef
46.
Shimoda M, Ota M, Okada Y. Isolation of cancer stem cells by side population method. Methods Mol Biol. 2018;1692:49–59.PubMedCrossRef
47.
Harrison H, Farnie G, Howell SJ, et al. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010;70:709–18.PubMedPubMedCentralCrossRef
48.
Shaker H, Harrison H, Clarke R, et al. Tissue Factor promotes breast cancer stem cell activity in vitro. Oncotarget. 2017;8:25915–27.PubMedCrossRef
49.
Calvet CY, Andre FM, Mir LM. The culture of cancer cell lines as tumorspheres does not systematically result in cancer stem cell enrichment. PLoS One. 2014;9:e89644.PubMedPubMedCentralCrossRef
50.
Tavare R, Wu WH, Zettlitz KA, et al. Enhanced immunoPET of ALCAM-positive colorectal carcinoma using site-specific (6)(4)Cu-DOTA conjugation. Protein Eng Des Sel. 2014;27:317–24.PubMedPubMedCentralCrossRef
51.
Horst D, Kriegl L, Engel J, Kirchner T, Jung A. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009;27:844–50.PubMedCrossRef
52.
Akbari-Birgani S, Paranjothy T, Zuse A, et al. Cancer stem cells, cancer-initiating cells and methods for their detection. Drug Discov Today. 2016;21:836–42.PubMedCrossRef
53.
Zhang Z, Li M, Chen F, et al. Probe-based confocal laser endomicroscopy for imaging TRAIL-expressing mesenchymal stem cells to monitor colon xenograft tumors in vivo. PLoS One. 2016;11:e0162700.PubMedPubMedCentralCrossRef
54.
Roy K, Kanwar RK, Kanwar JR. LNA aptamer based multi-modal, Fe3O4-saturated lactoferrin (Fe3O4-bLf) nanocarriers for triple positive (EpCAM, CD133, CD44) colon tumor targeting and NIR. MRI and CT imaging. Biomaterials. 2015;71:84–99.PubMed
55.
Van Dort ME, Rehemtulla A, Ross BD. PET and SPECT imaging of tumor biology: new approaches towards oncology drug discovery and development. Curr Comput Aided Drug Des. 2008;4:46–53.PubMedPubMedCentralCrossRef
56.
Liu Y, Jin X, Lan X, et al. SPECT imaging of colorectal cancer by targeting CD 133 receptor with 99mTc-labeled monoclonal antibody. Q J Nucl Med Mol Imaging. 2019;63:216–24.PubMed
57.
Jin ZH, Sogawa C, Furukawa T, et al. Basic studies on radioimmunotargeting of CD133-positive HCT116 cancer stem cells. Mol Imaging. 2012;11:445–50.PubMedCrossRef
58.
Mccabe KE, Liu B, Marks JD, et al. An engineered cysteine-modified diabody for imaging activated leukocyte cell adhesion molecule (ALCAM)-positive tumors. Mol Imaging Biol. 2012;14:336–47.PubMedPubMedCentralCrossRef
59.
Garza-Trevino EN, Said-Fernandez SL, Martinez-Rodriguez HG. Understanding the colon cancer stem cells and perspectives on treatment. Cancer Cell Int. 2015;15:2.PubMedPubMedCentralCrossRef
60.
Li CJ, Zhang X, Fan GW. Updates in colorectal cancer stem cell research. J Cancer Res Ther. 2014;10(Suppl):233–9.PubMed
61.
Gaedicke S, Braun F, Prasad S, et al. Noninvasive positron emission tomography and fluorescence imaging of CD133+ tumor stem cells. Proc Natl Acad Sci U S A. 2014;111:E692–701.PubMedPubMedCentralCrossRef
62.
Khemthongcharoen N, Jolivot R, Rattanavarin S, Piyawattanametha W. Advances in imaging probes and optical microendoscopic imaging techniques for early in vivo cancer assessment. Adv Drug Deliv Rev. 2014;74:53–74.PubMedCrossRef
Metadata
Title
Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model
Authors
Siao-Syun Guan
Cheng-Tien Wu
Tse-Zung Liao
Tsai-Yueh Luo
Kun-Liang Lin
Shing-Hwa Liu
Publication date
01-12-2020
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-020-0597-3

Other articles of this Issue 1/2020

EJNMMI Research 1/2020 Go to the issue

Case report

Extravasation of [177Lu]Lu-DOTATOC: case report and discussion

Original research

Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer

Original research

Evaluation of camera-based freehand SPECT in preoperative sentinel lymph node mapping for melanoma patients

Original research

177Lu radiolabeling and preclinical theranostic study of 1C1m-Fc: an anti-TEM-1 scFv-Fc fusion protein in soft tissue sarcoma

Original research

[18F]-Fluciclovine PET discrimination of recurrent intracranial metastatic disease from radiation necrosis

Original research

Fluorescence labeling of a NaV1.7-targeted peptide for near-infrared nerve visualization